poisar

Stocks · News reference

CareDx Announces Publication of Third KOAR Analysis in Transplantation

CareDx, Inc. announced the publication of a new analysis from its Kidney Allograft Outcomes AlloSure Registry (KOAR) in the journal Transplantation.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CDNA
Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. CareDx, Inc. Files Form 144

    CareDx, Inc. filed a Form 144 with the SEC on November 5, 2026, as reported by StreetInsider.

    CDNA
  2. Zacks.Com

    CareDx Q3 Earnings Call Highlights Raised '26 Outlook & Testing Growth

    CareDx raised its 2026 revenue guidance to $520M-$530M and adjusted EBITDA outlook to $90M-$100M, driven by strong transplant testing demand with volumes up 21% to 50,750. The company's specialty oncology business (NavDx) contributed $12.5M in Q3 revenues with 37% year-over-year growth. Management is preparing new molecular diagnostics AlloHeme and HistoMap Kidney for 2027 commercialization while targeting higher reimbursement rates per test.

    CDNA
  5. Joe Tenebruso

    Why CareDx Stock Soared Today

    CareDx stock surged over 22% after reporting strong Q3 2026 earnings with 39% revenue growth to $139 million, driven by a 65% jump in testing services revenue and 51% increase in testing volumes. The company raised its full-year revenue guidance to $525 million (38% growth) and boosted adjusted EBITDA targets to $90-100 million, reflecting growing clinical interest in precision medicine diagnostics.

    CDNA